HRP20200056T1 - Postupci za liječenje ili sprječavanje migrenske glavobolje - Google Patents
Postupci za liječenje ili sprječavanje migrenske glavobolje Download PDFInfo
- Publication number
- HRP20200056T1 HRP20200056T1 HRP20200056TT HRP20200056T HRP20200056T1 HR P20200056 T1 HRP20200056 T1 HR P20200056T1 HR P20200056T T HRP20200056T T HR P20200056TT HR P20200056 T HRP20200056 T HR P20200056T HR P20200056 T1 HRP20200056 T1 HR P20200056T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- receptor antibody
- binding fragment
- cgrp receptor
- use according
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims 9
- 206010027599 migraine Diseases 0.000 title claims 9
- 238000000034 method Methods 0.000 title claims 4
- 102000005962 receptors Human genes 0.000 claims 28
- 108020003175 receptors Proteins 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 26
- 239000000872 buffer Substances 0.000 claims 2
- 230000001667 episodic effect Effects 0.000 claims 2
- 238000009117 preventive therapy Methods 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Treatment And Processing Of Natural Fur Or Leather (AREA)
Claims (18)
1. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu u
(a) postupku za sprječavanje ili smanjenje javljanja migrenske glavobolje kod pacijenta kojem je potrebno, ili
(b) postupku za profilaktičko liječenje pacijenta zbog migrene
naznačeno time što postupak uključuje primjenu pacijentu protutijela anti-CGRP receptora ili njegovog ulomka koji veže antigen u dozi od oko 35 mg do oko 210 mg jednom mjesečno, pri čemu protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen sadrži CDRH1 koja ima sekvencu SEQ ID NO:14, CDRH2 koja ima sekvencu SEQ ID NO:23, CDRH3 koja ima sekvencu SEQ ID NO:34, CDRL1 koja ima sekvencu SEQ ID NO:44, CDRL2 koja ima sekvencu SEQ ID NO:55, i CDRL3 koja ima sekvencu SEQ ID NO:65.
2. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 1, naznačeno time što doza iznosi oko 70 mg do oko 140 mg jednom mjesečno.
3. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 1, naznačeno time što doza iznosi oko 70 mg jednom mjesečno.
4. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 1 naznačeno time što doza iznosi oko 140 mg jednom mjesečno.
5. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen primjenjuje putem potkožne injekcije.
6. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen treba davati pacijentu s autoinjektorom ili špricom prethodno napunjenom s protutijelom anti-CGRP receptora ili njegovim ulomkom koji veže antigen.
7. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time što pacijent ima ili mu je dijagnosticirana epizodna migrena.
8. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 7, naznačeno time što koji ima ili mu je dijagnosticirana epizodna migrena ima najmanje četiri, ali manje od petnaest dana migrenske glavobolje mjesečno.
9. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time što pacijent ima ili mu je dijagnosticirana kronična migrena.
10. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time što pacijent prethodno nije primio profilaktičku terapiju za migrenske glavobolje.
11. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time što pacijent nije uspio ili ima netoleranciju na barem jednu drugu profilaktičku terapiju migrenske glavobolje.
12. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 11 naznačeno time što druga profilaktička terapija migrenske glavobolje je antiepileptik, triciklički antidepresiv ili beta blokator.
13. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeno time što protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen sadrži varijabilnu regiju teškog lanca (VH) koja sadrži sekvencu SEQ ID NO:92, i varijabilnu regiju lakog lanca (VL) koja sadrži sekvencu SEQ ID NO:80.
14. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačeno time što protutijelo anti-CGRP receptora sadrži teški lanac koji sadrži sekvencu SEQ ID NO:105, te lagani lanac koji sadrži sekvencu SEQ ID NO:123.
15. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačeno time što je protutijelo anti-CGRP receptora monoklonsko lgG1 ili monoklonsko lgG2 protutijelo.
16. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 15 , naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen daje u farmaceutskom pripravku koji sadrži pufer, surfaktant, i sredstvo za stabilizaciju.
17. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 16 naznačeno time što je pufer acetatni pufer, surfaktant je polisorbat 20 ili polisorbat 80, a sredstvo za stabilizaciju je saharoza.
18. Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 3 ili 4, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen daje pacijentu pomoću jedne potkožne injekcije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152708P | 2015-04-24 | 2015-04-24 | |
EP15754071.7A EP3285803B1 (en) | 2015-04-24 | 2015-08-10 | Methods for treating or preventing migraine headache |
PCT/US2015/044479 WO2016171742A1 (en) | 2015-04-24 | 2015-08-10 | Methods for treating or preventing migraine headache |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200056T1 true HRP20200056T1 (hr) | 2020-04-03 |
Family
ID=53969433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200056TT HRP20200056T1 (hr) | 2015-04-24 | 2020-01-14 | Postupci za liječenje ili sprječavanje migrenske glavobolje |
Country Status (30)
Country | Link |
---|---|
US (3) | US10259877B2 (hr) |
EP (2) | EP3653225A1 (hr) |
JP (4) | JP6392471B2 (hr) |
KR (1) | KR102464415B1 (hr) |
CN (2) | CN108156814B (hr) |
AU (2) | AU2015392215B2 (hr) |
BR (1) | BR112017022772A2 (hr) |
CA (1) | CA2984254C (hr) |
CL (1) | CL2017002686A1 (hr) |
CY (1) | CY1123211T1 (hr) |
DK (1) | DK3285803T3 (hr) |
ES (1) | ES2771925T3 (hr) |
HK (1) | HK1250914A1 (hr) |
HR (1) | HRP20200056T1 (hr) |
HU (1) | HUE048528T2 (hr) |
IL (2) | IL255114B (hr) |
JO (2) | JOP20200116A1 (hr) |
LT (1) | LT3285803T (hr) |
MA (2) | MA51815A (hr) |
MX (2) | MX2017013627A (hr) |
PH (1) | PH12017501934A1 (hr) |
PL (1) | PL3285803T3 (hr) |
PT (1) | PT3285803T (hr) |
RS (1) | RS59912B1 (hr) |
RU (1) | RU2707745C2 (hr) |
SG (2) | SG11201708607WA (hr) |
SI (1) | SI3285803T1 (hr) |
TW (2) | TWI728953B (hr) |
WO (1) | WO2016171742A1 (hr) |
ZA (1) | ZA201707179B (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
CA2943551A1 (en) | 2014-03-21 | 2015-09-24 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
RU2770066C2 (ru) | 2017-03-02 | 2022-04-14 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида |
US20200207844A1 (en) * | 2017-09-12 | 2020-07-02 | Igc Bio, Inc. | Anti-vegf antibody |
US10738110B2 (en) | 2018-01-12 | 2020-08-11 | Amgen Inc. | PAC1 antibodies and uses thereof |
SG11202009629YA (en) * | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
EP4302828A3 (en) * | 2018-07-05 | 2024-01-17 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists and clostridial derivatives |
JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
MA55815A (fr) * | 2019-05-02 | 2022-03-09 | H Lundbeck As | Traitement de céphalées à l'aide d'anticorps anti-cgrp |
US20210121541A1 (en) | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
WO2021005493A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders |
WO2021005497A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders |
AU2020405091A1 (en) * | 2019-12-18 | 2022-07-14 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
AU673347B2 (en) | 1992-03-17 | 1996-11-07 | Novartis Ag | Genetically engineered antibodies |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | カルシトニンレセプター |
US5785682A (en) | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
AU6596096A (en) | 1996-07-23 | 1998-02-10 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
FR2821080B1 (fr) | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques |
WO2003027252A2 (en) | 2001-09-27 | 2003-04-03 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
EA008744B1 (ru) | 2002-08-12 | 2007-08-31 | Актавис Груп Хф. | Применение соединений антагонистов кальцитонин генсвязанного пептида (cgrp) для лечения псориаза |
US20040176577A1 (en) | 2002-09-10 | 2004-09-09 | Eva Rojer | Immunoassays for specific determination of SCCA isoforms |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
CA2849552A1 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
RS52036B (en) | 2004-12-21 | 2012-04-30 | Medimmune Limited | ANGIOPOETIN-2 ANTIBODIES AND ITS USES |
DE102004063753A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
WO2006134692A1 (ja) | 2005-06-16 | 2006-12-21 | Univ Shinshu | アドレノメデュリンを有効成分として含む血管新生剤 |
GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
ME00419B (me) * | 2005-11-14 | 2011-10-10 | Rinat Neuroscience Corp | Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja |
CA2629415A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam tricyclic cgrp receptor antagonists |
WO2007076336A1 (en) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
BRPI0715141A2 (pt) | 2006-08-03 | 2013-06-04 | Astrazeneca Ab | agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado |
CA2683581A1 (en) | 2007-04-11 | 2008-10-23 | Merck & Co., Inc. | Cgrp receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups |
WO2008130524A1 (en) | 2007-04-16 | 2008-10-30 | Merck & Co., Inc. | Aryl heterocyclic cgrp receptor antagonists |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
MX2010009724A (es) | 2008-03-04 | 2010-09-28 | Pfizer Ltd | Procedimientos de tratamiento del dolor inflamatorio-. |
AU2009257733A1 (en) | 2008-06-12 | 2009-12-17 | Merck Sharp & Dohme Corp. | Branched 3- and 6-substituted quinolines as CGRP receptor antagonists |
FR2934597B1 (fr) | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
JP2012502995A (ja) | 2008-09-18 | 2012-02-02 | メルク・シャープ・エンド・ドーム・コーポレイション | 二環式ジヒドロイミダゾロンcgrp受容体アンタゴニスト |
EP2340025B1 (en) | 2008-10-03 | 2014-10-15 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
JO3330B1 (ar) | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
JOP20190250A1 (ar) * | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
DK2709662T3 (da) * | 2011-05-20 | 2019-11-04 | Alderbio Holdings Llc | Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré |
ES2893073T3 (es) | 2011-05-20 | 2022-02-07 | H Lundbeck As | Composiciones anti CGRP y uso de las mismas |
CN107827982B (zh) * | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
JP6283408B2 (ja) | 2013-03-15 | 2018-02-21 | アムジェン インコーポレイテッド | ヒトpac1抗体 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
CA2943551A1 (en) | 2014-03-21 | 2015-09-24 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
UY36302A (es) * | 2014-09-15 | 2016-04-29 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas |
-
2015
- 2015-04-24 JO JOP/2020/0116A patent/JOP20200116A1/ar unknown
- 2015-08-07 TW TW104125845A patent/TWI728953B/zh active
- 2015-08-07 TW TW110115984A patent/TWI799849B/zh active
- 2015-08-10 MA MA051815A patent/MA51815A/fr unknown
- 2015-08-10 AU AU2015392215A patent/AU2015392215B2/en active Active
- 2015-08-10 ES ES15754071T patent/ES2771925T3/es active Active
- 2015-08-10 CN CN201580081186.0A patent/CN108156814B/zh active Active
- 2015-08-10 MX MX2017013627A patent/MX2017013627A/es unknown
- 2015-08-10 SG SG11201708607WA patent/SG11201708607WA/en unknown
- 2015-08-10 PT PT157540717T patent/PT3285803T/pt unknown
- 2015-08-10 SG SG10202004282RA patent/SG10202004282RA/en unknown
- 2015-08-10 CA CA2984254A patent/CA2984254C/en active Active
- 2015-08-10 JP JP2017555506A patent/JP6392471B2/ja active Active
- 2015-08-10 WO PCT/US2015/044479 patent/WO2016171742A1/en active Application Filing
- 2015-08-10 MA MA41932A patent/MA41932B1/fr unknown
- 2015-08-10 RU RU2017140789A patent/RU2707745C2/ru active
- 2015-08-10 EP EP19212188.7A patent/EP3653225A1/en active Pending
- 2015-08-10 EP EP15754071.7A patent/EP3285803B1/en active Active
- 2015-08-10 DK DK15754071.7T patent/DK3285803T3/da active
- 2015-08-10 KR KR1020177034051A patent/KR102464415B1/ko active IP Right Grant
- 2015-08-10 PL PL15754071T patent/PL3285803T3/pl unknown
- 2015-08-10 RS RS20200165A patent/RS59912B1/sr unknown
- 2015-08-10 HU HUE15754071A patent/HUE048528T2/hu unknown
- 2015-08-10 LT LTEP15754071.7T patent/LT3285803T/lt unknown
- 2015-08-10 SI SI201531065T patent/SI3285803T1/sl unknown
- 2015-08-10 BR BR112017022772-0A patent/BR112017022772A2/pt not_active Application Discontinuation
- 2015-08-10 CN CN202110748961.0A patent/CN113908268A/zh active Pending
-
2016
- 2016-03-03 JO JOP/2016/0034A patent/JO3559B1/ar active
- 2016-04-22 US US15/136,736 patent/US10259877B2/en active Active
-
2017
- 2017-10-18 IL IL255114A patent/IL255114B/en unknown
- 2017-10-23 CL CL2017002686A patent/CL2017002686A1/es unknown
- 2017-10-23 MX MX2021013327A patent/MX2021013327A/es unknown
- 2017-10-23 ZA ZA2017/07179A patent/ZA201707179B/en unknown
- 2017-10-23 PH PH12017501934A patent/PH12017501934A1/en unknown
-
2018
- 2018-08-10 HK HK18110282.6A patent/HK1250914A1/zh unknown
- 2018-08-21 JP JP2018154482A patent/JP6707590B2/ja active Active
-
2019
- 2019-02-27 US US16/287,533 patent/US11466090B2/en active Active
-
2020
- 2020-01-14 HR HRP20200056TT patent/HRP20200056T1/hr unknown
- 2020-02-11 CY CY20201100128T patent/CY1123211T1/el unknown
- 2020-05-20 JP JP2020087893A patent/JP2020143115A/ja active Pending
-
2022
- 2022-03-07 IL IL291153A patent/IL291153B2/en unknown
- 2022-06-14 JP JP2022095538A patent/JP2022126724A/ja active Pending
- 2022-07-06 AU AU2022204866A patent/AU2022204866A1/en active Pending
- 2022-09-02 US US17/902,168 patent/US20230020514A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200056T1 (hr) | Postupci za liječenje ili sprječavanje migrenske glavobolje | |
JP2020503260A5 (hr) | ||
HRP20210440T1 (hr) | Kombinirana terapija za rak | |
RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
JP2020099324A5 (hr) | ||
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
JP2017514461A5 (hr) | ||
HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
AR109298A1 (es) | Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso | |
JP2017501157A5 (hr) | ||
JP2020518600A5 (hr) | ||
HRP20231134T1 (hr) | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu | |
JP2018064580A5 (hr) | ||
HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
JP2018534933A5 (hr) | ||
RU2015112576A (ru) | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 | |
RU2016128726A (ru) | Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20 | |
JP2017514795A5 (hr) | ||
JP2015529225A5 (hr) | ||
AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
RU2016100892A (ru) | Антитела против tweakr и их применение |